Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients

H. I. Robins, J. D. Cohen, C. L. Schmitt, K. D. Tutsch, C. Feierabend, R. Z. Arzoomanian, D. Alberti, F. D'Oleire, W. Longo, C. Heiss, D. Rushing, R. Love, D. Spriggs

Research output: Contribution to journalArticle

78 Scopus citations


Purpose: To evaluate the biologic interactions and toxicities of carboplatin combined with 41.8°C whole-body hyperthermia (WBH) for 60 minutes in a phase I clinical trial. Patients and Methods: Thirty assessable patients with cancer refractory to conventional therapy were treated. During induction therapy, patients received WBH alone in week 1, WBH plus carboplatin in week 2, and carboplatin alone in week 5. Carboplatin dose was escalated (three patients per group) as follows: 100, 150, 200, 250, 300, 350, 400, 480, and 575 mg/m2; three additional patients were entered at 480 mg/m2. Carboplatin was administered at target temperature. Results: Comparisons of the mean/median WBC and platelet nadirs for carboplatin alone and carboplatin plus WBH demonstrated no enhancing effect by WBH. Toxicities including nausea and/or vomiting, as well as myelosuppression, were within acceptable limits, allowing for escalation to a dose of 575 mg/m2; three of three patients at this dose level experienced grade 4 myelosuppression with no associated infection or bleeding. No renal toxicity was observed. Analysis of platinum in plasma ultrafiltrate and urine showed only slight effects of WBH on the pharmacokinetics and renal excretion of platinum. Responses included the following: lung-minor response (200 mg/m2); gastrointestinal neuroendocrine-complete response (CR) (400 mg/m2); pancreatic-partial response (PR) (480 mg/m2); small bowel-PR (575 mg/m2); ovarian-CR, two patients (575 mg/m2), with marker data suggesting WBH enhancement of carboplatin cytotoxicity. Another three patients experienced clinical improvement after WBH plus carboplatin, but progression with carboplatin alone (lung, 400 mg/m2; gastrointestinal neuroendocrine, 480 mg/m2; melanoma, 480 mg/m2). Conclusion: We conclude that carboplatin with WBH is well tolerated even at conventional carboplatin doses. Clinical results are consistent with preclinical predictions of an increased therapeutic index for this combination, which encourages future clinical studies.

Original languageEnglish (US)
Pages (from-to)1787-1794
Number of pages8
JournalJournal of Clinical Oncology
Issue number9
StatePublished - 1993

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Robins, H. I., Cohen, J. D., Schmitt, C. L., Tutsch, K. D., Feierabend, C., Arzoomanian, R. Z., Alberti, D., D'Oleire, F., Longo, W., Heiss, C., Rushing, D., Love, R., & Spriggs, D. (1993). Phase I clinical trial of carboplatin and 41.8°C whole-body hyperthermia in cancer patients. Journal of Clinical Oncology, 11(9), 1787-1794.